Current News

Contact | Print version | PDF version | Send article | RSS-Feed

UCB gains global rights pertaining to VEGFR-2 for CDP-791

08 Feb 2007 - UCB announced that UCB and ImClone Systems Incorporated have agreed to terminate their CDP-791 development agreement. UCB will enjoy freedom to operate rights globally to ImClone's intellectual property pertaining to vascular endothelial growth factor receptor-2 ("VEGFR-2") for CDP-791. In return, ImClone will receive a royalty on future sales of CDP-791, when UCB will commercialise this antibody.
 
UCB is currently evaluating CDP-791 for the treatment of non-small-cell lung cancer in a phase IIa clinical programme. CDP-791 is UCB's PEGylated diFab antibody designed to inhibit the function of a signaling pathway known to play a role in the formation of blood vessels in tumors by blocking VEGFR-2 from binding to molecules (ligands) that stimulate its activation.